Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eli Lilly & Co. (LLY) Shares Slide After Missing Estimates
August 4, 2022 11:06 AM EDTEli Lilly & Co. (NYSE: LLY) shares are down Thursday following its second-quarter earnings report, which saw it miss analyst estimates.
The drugmaker reported earnings of $1.25 per share, $0.46 below the analyst estimate of $1.71, while revenue came in at $6.49 billion versus the consensus estimate of $6.85... More
Eli Lilly & Co. (LLY) Misses Q2 EPS by 46c, Revenue Misses
August 4, 2022 6:27 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $1.25, $0.46 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $6.49 billion versus the consensus estimate of $6.85 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2022 EPS of $7.90-$8.05, versus the... More
